Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

Ipsen's DIRECTION Trial Shows Dysport's Longer Duration and Non-Inferior Safety

Ipsen announced late-breaking results from its Phase IV DIRECTION trial, the first head-to-head, double-blind study comparing Dysport (abobotulinumtoxinA) to Botox (onabotulinumtoxinA) in adults with upper limb spasticity (ULS). The trial demonstrated that Dysport achieved non-inferior safety compared to Botox, with treatment-emergent adverse event rates of 20.3% for Dysport versus 23.0% for Botox. Furthermore, Dysport showed a longer duration of effect, lasting 14.2 weeks compared to 13.8 weeks for Botox. These findings provide crucial comparative evidence for clinicians, reinforcing Dysport's established safety profile and its ability to offer more durable symptom control for ULS patients.

• Safety Non-Inferiority Confirmed: The DIRECTION trial's primary endpoint established Dysport's non-inferior safety profile compared to Botox in adult upper limb spasticity patients. Dysport reported a treatment-emergent adverse event rate of 20.3%, closely matching Botox's 23.0%. This outcome, with an adjusted difference of -2.7% (80%CI: -6.2%, 0.9%), supports the well-established safety of both botulinum toxin type A treatments and provides clinicians with robust comparative data for patient care decisions.
• Extended Duration of Effect: Dysport demonstrated a statistically significant longer duration of effect as a key secondary endpoint, lasting an average of 14.2 weeks compared to 13.8 weeks for Botox. This extended control, with an adjusted difference favoring Dysport (80%CI: 0.2, 5.9), is clinically meaningful for patients experiencing upper limb spasticity, as it can potentially reduce the frequency of breakthrough symptoms between injection cycles and improve overall quality of life and function.
• Rigorous Head-to-Head Trial Design: The DIRECTION trial is notable as the first prospective, head-to-head, double-blind, crossover study directly comparing Dysport and Botox in adult spasticity. Involving 464 patients across 72 sites in the USA, France, and Canada, the trial employed standardized, instrument-guided techniques and controlled for critical factors like volume, dilution, dose, and muscles treated. This rigorous design addresses long-standing evidence gaps, providing high-quality comparative data for the medical community.

Addressing the Unmet Need in Upper Limb Spasticity Treatment

Current treatment approaches for upper limb spasticity face significant challenges that limit optimal patient outcomes. These limitations span from fundamental research gaps to practical implementation barriers in clinical practice. Understanding these constraints is essential for developing more effective therapeutic strategies.

• Evidence gaps exist for combination therapies, with no available information on the effectiveness or individual contribution of botulinum toxin type A combined with physical and occupational therapy and neuromuscular electrical stimulation

• Functional outcome prediction remains difficult, as measuring and predicting improvement in active movement function of the affected upper limb presents ongoing challenges (Class III evidence, recommendation C)

• Clinical practice barriers impede treatment delivery, including clinicians' lack of time, limited financial resources, and insufficient evidence base for adjunctive therapies after botulinum toxin injection

• Treatment duration limitations affect long-term management, as botulinum toxin effects are transient while surgical interventions, though providing sustained benefits, carry significant risks and irreversibility

• Surgical options have substantial constraints, with dorsal rhizotomy requiring invasiveness, irreversible outcomes, and lifelong postoperative neurorehabilitation needs

• Terminology and pathophysiology understanding remains fragmented, as spasticity describes many unrelated syndromes sharing few common pathophysiologic mechanisms, making it impossible to define unified physiology or pharmacology

• Functional disability stems primarily from negative symptoms rather than spasticity itself in patients with spastic paresis, complicating treatment focus and outcome measurement approaches

The Rigorous Design of the DIRECTION Trial for ULS

Recent clinical trials investigating upper limb spasticity have employed diverse study designs ranging from large international observational cohorts to focused randomized controlled trials. These studies have consistently utilized the Modified Ashworth Scale as the primary spasticity assessment tool while incorporating functional outcome measures to evaluate treatment efficacy across different patient populations and interventions.

Dysport's Safety and Longer Duration of Effect in ULS

Recent studies have demonstrated the continued efficacy and safety profile of botulinum toxin treatments for upper limb spasticity across diverse patient populations. These investigations range from large-scale longitudinal analyses to innovative combination therapies, providing valuable insights for clinical practice.

• ULIS-III Study (2026) utilized repeated botulinum toxin A injections in 953 participants across an international, observational, 2-year longitudinal study, achieving treatment goals in 76.2% of injection cycles and demonstrating significant improvements in passive function scores for at least six cycles (p < 0.001) with evidence of cumulative benefit over successive treatments

• Pooled Analysis of IncobotulinumtoxinA Trials (2025) examined seven prospective, multicenter phase II/III trials in 267 older patients (≥65 years) with upper limb spasticity, showing statistically significant improvements in all spasticity patterns at week 4 (p < 0.05) with most improvements sustained at week 12, while maintaining general tolerability

• Multimodal Machine Learning Study (2026) compared ultrasound-guided botulinum toxin alone versus combination with vibration therapy in 200 post-stroke patients, revealing significantly greater reductions in Modified Ashworth Scale scores for combination therapy (mean ΔMAS: 1.48 vs. 1.12, p < 0.01) along with improved functional outcomes on Fugl-Meyer Assessment and Barthel Index scores

• Pediatric Safety Case Series (2025) documented muscle fasciculations as a potential transient adverse effect in three cerebral palsy patients receiving botulinum toxin from age 2 years, requiring clinical monitoring but considered non-harmful and manageable with professional stretching interventions

Dysport's Head-to-Head Win: A New Edge in ULS Treatment

The recent announcement from Ipsen regarding its Phase IV DIRECTION trial results marks a pivotal moment in the treatment landscape for upper limb spasticity (ULS). For the first time, clinicians have access to head-to-head, double-blind comparative data directly pitting Dysport against Botox, the two leading botulinum toxin products in this indication. This level of rigorous comparison is invaluable, moving beyond indirect comparisons and providing concrete evidence to guide treatment decisions.

The trial's findings underscore Dysport's established safety profile, demonstrating non-inferiority to Botox with comparable rates of treatment-emergent adverse events. While a 20.3% adverse event rate for Dysport is a factor for patient counseling, its equivalence to Botox's 23.0% rate reinforces confidence in its tolerability. Crucially, Dysport showed a statistically significant longer duration of effect, lasting 14.2 weeks compared to 13.8 weeks for Botox. This seemingly small difference of 0.4 weeks, when extrapolated over a patient's treatment journey, could translate into fewer injections per year, offering a tangible benefit in terms of patient convenience and potentially reducing healthcare resource utilization.

For Ipsen, these results provide a powerful tool for market differentiation. The ability to claim a longer duration of effect, backed by robust head-to-head data, strengthens Dysport's value proposition in a highly competitive market. However, the clinical significance of this marginal duration advantage will be key to driving adoption. Pharma teams will need to effectively communicate how this extended duration translates into meaningful improvements in patient quality of life or functional outcomes, beyond just the injection interval. Furthermore, while safety and duration are critical, the absence of comparative data on other functional efficacy measures from this specific trial means that a holistic comparative profile still requires consideration of other studies. This strategic insight will be crucial for Ipsen as it seeks to solidify Dysport's position and potentially expand its market share in the ULS therapeutic area.